Roche's Genentech Vabysmo New Long-Term Data Shows Sustained Retinal Drying And Vision Improvements In Retinal Vein Occlusion (RVO)
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech has announced new long-term data for Vabysmo, showing sustained improvements in retinal drying and vision for patients with Retinal Vein Occlusion (RVO). The data indicates that up to 60% of patients could extend treatment intervals to three or four months. Detailed results from two global Phase III RVO studies will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.

January 26, 2024 | 6:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's Genentech Vabysmo shows positive long-term data for RVO treatment, potentially strengthening its market position and boosting future revenues.
The positive long-term data for Vabysmo is likely to increase its adoption among healthcare providers, leading to higher sales and a positive impact on Roche's stock price in the short term. The ability to extend treatment intervals may also enhance its competitive edge in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100